KYAN Technologies is a Singapore-based precision medicine company focused on improving cancer treatment and drug development. Its flagship platform, Optim.AI™, uses functional drug sensitivity testing and small-data artificial intelligence to assess how an individual patient’s tumor may respond to treatment options. Designed to work with limited tumor tissue, the platform supports oncologists with patient-specific clinical decision support and is also available to patients through dedicated resources.

For biopharma and research organizations, KYAN offers research and development services, drugs for research, biobank resources, and tools such as the Optim.AI Drug Panel Builder. The company describes its technology as helping to address large, complex search spaces in treatment selection and drug development. Its scientific founders developed the technology at the University of California, Los Angeles, and the National University of Singapore. KYAN provides information for clinicians, patients, and researchers, including specimen requirements, FAQs, publications, workshops, and podcasts. Its laboratory is accredited by the College of American Pathologists and licensed by Singapore’s Ministry of Health as a clinical laboratory.